{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T04:00:50Z","timestamp":1648872050391},"reference-count":13,"publisher":"Georg Thieme Verlag KG","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n          Klinische Manifestation\u2002Die kardiale Transthyretin-Amyloidose (ATTR) ist als seltene Ursache einer Kardiomyopathie Teil einer unterdiagnostizierten Systemerkrankung. F\u00fcr die kardiale Transthyretin-Amyloidose, bei der es zur Ablagerung von fehlgefaltetem Transthyretin kommt, entweder als Wildtyp (wtATTR) oder mutierte (mATTR) Form, sind seit kurzem evidenzbasierte Therapiem\u00f6glichkeiten mit Verlangsamung der Kardiomyopathie-Progression und deutlicher Reduktion der Hospitalisierungsraten verf\u00fcgbar. Daher ist es wichtig, diese schwerwiegende Erkrankung fr\u00fchzeitig zu diagnostizieren.<\/jats:p><jats:p>\n          Diagnostik\u2002Mittels Bildgebung (kardiale MRT oder szintigrafische Verfahren) sowie Immunfixation mit Bestimmung der freien Leichtketten ist ein klinisches Screening einfach m\u00f6glich, bevor mittels Biopsie und\/oder Genetik die definitive Diagnose gestellt wird. Eine interdisziplin\u00e4re Aufarbeitung bei Verdacht auf kardiale Amylodiose unter Einbezug von H\u00e4matoonkologie, Nephrologie, Neurologie und weiteren Disziplinen ist hierbei unabdingbar.<\/jats:p><jats:p>\n          Therapie\u2002Bei Patienten mit einer kardialen Amyloidose kann eine Herzinsuffizienz-Therapie mit Betablocker, Renin-Angiotensin-Aldosteron-Inhibitoren und Diuretika erfolgen, sollte allerdings aufgrund unerw\u00fcnschter Nebenwirkungen vorsichtig erfolgen. Studien haben in den letzten Jahren die Wirksamkeit eines Tetramer-Stabilisators sowie von TTR-mRNA-interferierenden Therapeutika zur medikament\u00f6sen Therapie der ATTR-Amyloidose gezeigt \u2013 9\n          10. Eine spezifische Zulassung zur Therapie der kardialen ATTR-Amyloidose existiert seit neuestem f\u00fcr den Tetramer-Stabilisator Tafamidis 11\n          12.<\/jats:p>","DOI":"10.1055\/a-1019-2072","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T22:31:20Z","timestamp":1597357880000},"page":"1162-1168","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostik bei Verdacht auf kardiale Amyloidose"],"prefix":"10.1055","volume":"145","author":[{"given":"Korinna","family":"Feldmann","sequence":"additional","affiliation":[{"name":"Abteilung Kardiologie und Angiologie am UKGM Gie\u00dfen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian W.","family":"Hamm","sequence":"additional","affiliation":[{"name":"Abteilung Kardiologie und Angiologie am UKGM Gie\u00dfen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"A\u00dfmus","sequence":"additional","affiliation":[{"name":"Abteilung Kardiologie und Angiologie am UKGM Gie\u00dfen"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12181-019-00344-5","article-title":"Diagnostik und Therapie der kardialen Amyloidose: Positionspapier der Deutschen Gesellschaft f\u00fcr Kardiologie \u2013 Herz- und Kreislaufforschung (DGK)","volume":"13","author":"A Yilmaz","year":"2019","journal-title":"Der Kardiologe"},{"issue":"09","key":"ref2","doi-asserted-by":"crossref","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis","volume":"12","author":"M S Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"e006169","DOI":"10.1161\/CIRCHEARTFAILURE.119.006169","article-title":"Cardiac Amyloidosis A Rare Disease in Older Adults Hospitalized for Heart Failure?","volume":"12","author":"J M Griffin","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"16","key":"ref4","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/eurheartj\/ehz057","article-title":"Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis","volume":"40","author":"M P van den Berg","year":"2019","journal-title":"Eur Heart J"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4103\/wjnm.WJNM_9_19","article-title":"Bone scintigraphy imaging of cardiac amyloidosis","volume":"18","author":"I M Kuria","year":"2019","journal-title":"World J Nucl Med"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000495455","article-title":"Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis","volume":"141","author":"I Vaxman","year":"2019","journal-title":"Acta Haematol"},{"issue":"14","key":"ref7","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis","volume":"135","author":"M S Maurer","year":"2017","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1055\/a-0848-9610","article-title":"Neue Therapieoptionen f\u00fcr die heredit\u00e4re Transthyretin-Amyloidose","volume":"144","author":"A Zibert","year":"2019","journal-title":"Dtsch Med Wochenschr"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"D Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"M D Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"e004769","DOI":"10.1161\/CIRCHEARTFAILURE.117.004769","article-title":"TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis","volume":"11","author":"H Rosenblum","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"M S Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an\u00a0RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis","volume":"139","author":"S D Solomon","year":"2019","journal-title":"Circulation"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1019-2072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T22:32:07Z","timestamp":1597357927000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1019-2072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":13,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2020,8,13]]},"published-print":{"date-parts":[[2020,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1019-2072","relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}